Differential expression of mRNA and lncRNA in erlotinib-resistant non-small cell lung cancer cells

doi:10.3877/cma.j.issn.1674-6902.2020.03.015

Abstract

Abstract:

Objective

To identify the differential expression of mRNA and lncRNA in the erlotinib-resistant non-small cell lung cancer cells.

Methods

GSE80344 microarray datasets were selected from the Gene Expression Omnibus (GEO) database including the data from erlotinib-resistant HCC827 cells and sensitive cells. The aberrantly-expressed mRNAs and lncRNAs were analyzed by GEO2R and probe ID matching. The screening criteria were |Fold change|>1.5 and P value<0.01. The possible mechanisms of action of dysregulatory mRNAs and lncRNAs were investigated by Panther (http: //www.pantherdb.org), KEGG (http: //www.kegg.jp/), STRING (http: //string-db.org), and other databases. The candidate key mRNAs and lncRNAs obtained by screening were verified by survival analysis using the data from the TCGA database (https: //cancergenome.nih.gov/).

Results

Compared with the sensitive cells, there were 644 differentially-expressed mRNAs and 367 differentially-expressed lncRNAs in the erlotinib-resistant HCC827 cells, respectively, of which 128 mRNAs were up-regulated and 516 mRNAs were down-regulated. And 137 lncRNAs were up-regulated and 230 lncRNAs were down-regulated. These mRNAs and lncRNAs were mainly involved in the signaling pathways closely related to cancers, such as PI3K-Akt, Ras, MAPK, ECM receptor interactions, and so on. Database-based verification confirmed the screening results.

Conclusion

The screened out mRNAs and lncRNAs can provide theoretical and preliminary experimental bases for the further study on the mechanisms of EGFR-TKIs resistance of non-small cell lung cancer.

Key words: Non-small cell lung cancer, Erlotinib drug resistance, Differential expression, IncRNA analysis

Shubin Li, Hong Yu, Gengyue Zhang. Differential expression of mRNA and lncRNA in erlotinib-resistant non-small cell lung cancer cells[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(03): 365-370.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.03.015

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I03/365

Figures/Tables 3

References 28

1	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
2	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
3	陈艳丽，王媛媛，张　勇，等. 中晚期非小细胞肺癌患者化疗前后T淋巴细胞亚群表达差异分析及临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 13-17.
4	Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer[J]. Trends cancer, 2016, 2(7): 350-364.
5	Fustaino V, Presutti D, Colombo T, et al. Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines[J]. Oncotarget, 2017, 8(61): 103340-103363.
6	Presutti D, Santini S, Cardinali B, et al. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells[J]. PloS one, 2015, 10(11): e0143333.
7	Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-2504.
8	Zhang X, Sun S, Pu JK, et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma[J]. Neurobiol Dis, 2012, 48(1): 1-8.
9	Xue W, Li L, Tian X, et al. Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer[J]. Oncotarget, 2017, 8(38): 62868-62879.
10	Wu Y, Yu DD, Hu Y, et al. Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray[J]. Oncol Rep, 2016, 35(6): 3371-3386.
11	Yang J, Lin J, Liu T, et al. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes[J]. Lung cancer, 2014, 85(2): 110-115.
12	Qu L, Ding J, Chen C, et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA[J]. Cancer cell, 2016, 29(5): 653-668.
13	Jin W, Chen L, Cai X, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1[J]. Oncol Rep, 2017, 37(1): 273-280.
14	Cheng N, Li X, Zhao C, et al. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer[J]. Oncol Rep, 2015, 33(2): 833-839.
15	Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease[J]. Transcription, 2014, 5(4): e944014.
16	Liu Z, Sun M, Lu K, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression[J]. PloS one, 2013, 8(10): e77293.
17	Liu J, Wan L, Lu K, et al. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma[J]. PloS one, 2015, 10(5): e0114586.
18	Chen J, Zhang K, Song H, et al. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells[J]. Oncotarget, 2016, 7(38): 62474-62489.
19	Ma P, Zhang M, Nie F, et al. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer[J]. Biomed Pharmacother, 2017, 87: 20-26.
20	Xia L, Huang W, Tian D, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma[J]. Hepatology (Baltimore, Md), 2013, 57(2): 610-624.
21	Cheng N, Cai W, Ren S, et al. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer[J]. Oncotarget, 2015, 6(27): 23582-23593.
22	Pan H, Jiang T, Cheng N, et al. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer[J]. Oncotarget, 2016, 7(31): 49948-49960.
23	Wang B, Jiang H, Wang L, et al. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway[J]. Oncol Lett, 2017, 13(5): 3494-3500.
24	Shi X, Sun M, Liu H, et al. A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer[J]. Mol Carcinog, 2015, 54(Suppl 1): E1-e12.
25	Dong S, Qu X, Li W, et al. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression[J]. J Hematol Oncol, 2015, 8: 43.
26	Byers LA, Diao L, Wang J, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance[J]. Clin Cancer Res, 2013, 19(1): 279-290.
27	Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer[J]. Nat Genet, 2012, 44(8): 852-860.
28	Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival[J]. Proc Natl Acad Sci U S A, 2006, 103(15): 5799-5804.

[1]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[2]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[3]	Yuan Wang, Yi Yang, Yunfei Mou, Fuqiang Ren, Xin Huang. Analysis of postoperative osimertinib targeted therapy in patients with resectable non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 657-660.
[4]	Ling Ma, Yinglong Li, Na Yue, Lifei Yang. Expression and clinical value of differential proteins in exosomes from non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(03): 327-330.
[5]	Xiaoqin Weng, Jiayang Qin, Yang Zhang, Jin Cui, Hong Shen. Effect of HIF-1α/VEGF-VEGFR2/Nrp-1 on Treg proliferation in NSCLC patients [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(06): 717-722.
[6]	Rui Xu, Yong Qian, Haiyan Zhang. Study on the mechanism of miR-515-5p enhanced the cisplatin sensitivity of NSCLC A549/DDP cells via targeting RING1 [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 559-563.
[7]	Xuan Wang, Lichun Cui, Shengqiang Dang. Effect of apatinib and Erica on the expression of immune cell surface molecules in patients with NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 554-558.
[8]	Zhiguo Yu, Bo Gong, Weihua Lu, Minfang Li. Silencing HIF-1α regulates MAPK/ERK pathway and inhibits metastasis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 573-578.
[9]	Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.
[10]	Bo Zhang, Bo Jin. Progress in research of Met as a target in non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 797-800.
[11]	Jingxiu Niu, Lihong Zhang, Hui Wang. Clinical study on the improvement of adverse reactions related to paclitaxel combined with cisplatin chemotherapy in advanced non-small cell lung cancer by grey screening method [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 774-778.
[12]	Kexin Tang, Xi Lin, Hong Shan. Doxorubicin-loaded fluorescent carbon dots with PEI passivation inhibited proliferation, migration and invasion of non-small cell lung cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 131-136.
[13]	Leilei Shen, Yang Liu. The staging evolution and treatment strategies of stage ⅠB non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(04): 246-254.
[14]	Xiao Liang, Lei Wang, Tao Jiang. Progress in surgical treatment of non-small cell lung cancer invading the chest wall [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 157-163.
[15]	Jianqiao Cai, Jing Huang, Lei Jiang. Double sleeve uniportal video-assisted thoracoscopic lobectomy—a retrospective study from shanghai pulmonary hospital [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 144-149.

Please choose a citation manager

Content to export